Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181584 | 0.86 | MAPK1 (0.48) | MAPK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL18629838 | 0.78 | SMN1; SMN2 (0.52) | MAPK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL22623459 | 0.78 | LMNA (0.43) | MAPK1RAB9APOLBHPGDLMNA | |
| SCHEMBL20181578 | 0.76 | CYP19A1 (0.46) | LMNANPSR1ALDH1A1ALOX15MAPT | |
| SCHEMBL20181613 | 0.76 | ALDH1A1 (0.50) | NPC1RAB9ASMN1; SMN2POLBHPGD | |
| SCHEMBL20181391 | 0.74 | LMNA (0.49) | MAPK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL22623399 | 0.74 | DRD2 (0.44) | NPC1RAB9ASMN1; SMN2POLBLMNA | |
| SCHEMBL21836689 | 0.74 | CDK2 (0.43) | NPC1RAB9APOLBLMNANPSR1 | |
| SCHEMBL21192277 | 0.74 | ALDH1A1 (0.40) | MAPK1RAB9ASMN1; SMN2POLBHPGD | |
| SCHEMBL22623470 | 0.73 | LMNA (0.43) | MAPK1NPC1RAB9APOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018090921-A1 | URAT1 INHIBITOR AND USE THEREOF | 江苏新元素医药科技有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | SLC14A1, SLC10A6, SLC10A1 | MAPK1 1850/4885NPC1 150/4885RAB9A 1783/4885 |
| US-10875865-B2 | URAT1 inhibitor and use thereof | SLC14A1, SLC10A6, SLC10A1 | MAPK1 1850/4885NPC1 150/4885RAB9A 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.